PL2733492T3 - Sposób wykrywania nowotworów - Google Patents

Sposób wykrywania nowotworów

Info

Publication number
PL2733492T3
PL2733492T3 PL14153299T PL14153299T PL2733492T3 PL 2733492 T3 PL2733492 T3 PL 2733492T3 PL 14153299 T PL14153299 T PL 14153299T PL 14153299 T PL14153299 T PL 14153299T PL 2733492 T3 PL2733492 T3 PL 2733492T3
Authority
PL
Poland
Prior art keywords
cancer detection
cancer
detection
Prior art date
Application number
PL14153299T
Other languages
English (en)
Inventor
Fumiyoshi Okano
Kana Suzuki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2733492T3 publication Critical patent/PL2733492T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL14153299T 2008-08-05 2009-08-05 Sposób wykrywania nowotworów PL2733492T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008202320 2008-08-05
EP14153299.4A EP2733492B1 (en) 2008-08-05 2009-08-05 Cancer detection method
EP09805010.7A EP2325648B1 (en) 2008-08-05 2009-08-05 Method for detecting cancer

Publications (1)

Publication Number Publication Date
PL2733492T3 true PL2733492T3 (pl) 2016-08-31

Family

ID=41663744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14153299T PL2733492T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów
PL09805010T PL2325648T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL09805010T PL2325648T3 (pl) 2008-08-05 2009-08-05 Sposób wykrywania nowotworów

Country Status (16)

Country Link
US (1) US11137401B2 (pl)
EP (2) EP2325648B1 (pl)
JP (2) JP5644110B2 (pl)
KR (2) KR101606779B1 (pl)
CN (1) CN102171570B (pl)
AU (2) AU2009278387B2 (pl)
BR (1) BRPI0911925B8 (pl)
CA (1) CA2732980C (pl)
DK (2) DK2325648T3 (pl)
ES (2) ES2471379T3 (pl)
HU (1) HUE027332T2 (pl)
MX (2) MX2011001445A (pl)
PL (2) PL2733492T3 (pl)
PT (1) PT2325648E (pl)
RU (2) RU2519089C2 (pl)
WO (1) WO2010016527A1 (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
PT2322221E (pt) 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
KR101805520B1 (ko) * 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2583627T3 (es) 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
PL2532364T3 (pl) * 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
BR112012018943A8 (pt) 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
CA2788716C (en) * 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
ES2634249T3 (es) * 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
MX348578B (es) * 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
PT2741085T (pt) * 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
HUE030137T2 (en) * 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
RU2595400C2 (ru) * 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
RU2624049C2 (ru) * 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
EP2818483B1 (en) * 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CA2864999C (en) * 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX360211B (es) * 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
CN104220095B (zh) * 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
CA2869123C (en) * 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
PL2876447T3 (pl) * 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP2876446B1 (en) * 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
EP3031826B1 (en) 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US20170322218A1 (en) * 2014-11-27 2017-11-09 Public University Corporation Yokohama City University Method and reagent for detecting ovarian clear cell adenocarcinoma
RU2611896C1 (ru) * 2016-03-10 2017-03-01 Федеральное государственное бюджетное учреждение здравоохранения Клиническая больница N 122 имени Л.Г. Соколова Федерального медико-биологического агентства (ФГБУЗ КБ N 122 им. Л.Г. Соколова ФМБА России) Способ диагностики лейомиомы мочевого пузыря
TWI782000B (zh) * 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
US20210107989A1 (en) * 2017-04-04 2021-04-15 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
RU2677064C1 (ru) * 2017-10-13 2019-01-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ определения границ резекции при лечении остеосаркомы
WO2020067261A1 (ja) * 2018-09-26 2020-04-02 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム
JP6875451B2 (ja) * 2018-09-26 2021-05-26 株式会社レナテック 犬のがんリスク評価方法及びがんリスク評価システム
AU2024242849A1 (en) 2023-03-28 2025-09-25 Toray Industries, Inc. Method for detecting cell membrane protein
JPWO2024204685A1 (pl) 2023-03-31 2024-10-03

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9102074D0 (sv) 1991-07-03 1991-07-03 Kabi Pharmacia Ab Tomour antigen specific antibody
DK0782709T3 (da) 1994-09-19 2010-03-29 Ricardo J Moro Detektering af cancer
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) * 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU3316600A (en) * 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) * 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
HK1045332A1 (zh) * 1999-04-02 2002-11-22 Corixa Corporation 用於治療和診斷肺癌的化合物及其使用方法
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
JP2004526401A (ja) * 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) * 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) * 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319709C2 (ru) 2001-07-17 2008-03-20 Рисерч Дивелопмент Фаундейшн Терапевтические агенты, содержащие проапоптозные белки
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) * 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
JP3869352B2 (ja) 2002-11-12 2007-01-17 日鉱金属株式会社 金属箔の熱量測定方法、表面特性の調整方法、レーザー穴開け方法又は熱量測定装置
WO2004047728A2 (en) * 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) * 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) * 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) * 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) * 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
PT1735348E (pt) 2004-03-19 2012-07-24 Imclone Llc Anticorpo anti-receptor do factor de crescimento humano
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) * 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
SI1839662T1 (sl) 2005-01-19 2010-07-30 Zeria Pharm Co Ltd Antitumorsko sredstvo
UA94899C2 (ru) * 2005-01-21 2011-06-25 Дженентек, Инк. Фиксированное дозирование антител к her
WO2006089212A2 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) * 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) * 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
WO2007095186A2 (en) * 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) * 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP4958580B2 (ja) 2007-02-21 2012-06-20 鹿島建設株式会社 シールド機、シールド機とセグメントの間のクリアランス測定方法
KR20100083768A (ko) 2007-10-25 2010-07-22 도레이 카부시키가이샤 암의 검출 방법
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
BRPI0912462B1 (pt) 2008-08-05 2022-03-22 Toray Industries, Inc Uso de um agente indutor de imunidade, uso de um polipeptídeo e uso de um vetor recombinante
PT2322221E (pt) * 2008-08-05 2014-09-19 Toray Industries Composição farmacêutica para tratamento e prevenção de cancro
BRPI0911925B8 (pt) 2008-08-05 2024-02-06 Toray Industries Método para detectar um câncer
AU2010285265B2 (en) 2009-08-19 2015-05-21 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
US8709418B2 (en) * 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
PL2532364T3 (pl) 2010-02-04 2016-11-30 Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112012018943A8 (pt) * 2010-02-04 2017-12-19 Toray Industries medicamento e método para o tratamento e/ou prevenção de um câncer
KR101805520B1 (ko) * 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
ES2583627T3 (es) * 2010-02-04 2016-09-21 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer
WO2012005550A2 (ko) 2010-07-08 2012-01-12 강원대학교산학협력단 담낭암 치료용 약제학적 조성물 및 이를 이용한 담낭암의 성장, 전이 억제 및 치료 방법
CN103261224B (zh) 2010-07-26 2015-10-07 瑟维尔实验室 用于肝癌治疗的方法和组合物
PT2741085T (pt) 2011-08-04 2017-06-30 Toray Industries Método para a deteção de cancro prancreático
RU2595400C2 (ru) 2011-08-04 2016-08-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
MX348578B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
RU2624049C2 (ru) 2011-08-04 2017-06-30 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественной опухоли
WO2013018886A1 (ja) 2011-08-04 2013-02-07 東レ株式会社 膵臓癌の治療及び／又は予防用医薬組成物
HUE030137T2 (en) 2011-08-04 2017-04-28 Toray Industries Pharmaceutical preparation for the treatment and / or prevention of cancer
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
CA2864999C (en) 2012-02-21 2020-06-30 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
MX360211B (es) 2012-02-21 2018-10-24 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2818483B1 (en) 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
CN104220095B (zh) 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
PL2876447T3 (pl) 2012-07-19 2020-05-18 Toray Industries, Inc. Sposób wykrywania nowotworu
EP3031826B1 (en) 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer

Also Published As

Publication number Publication date
KR20160039295A (ko) 2016-04-08
AU2015238877B2 (en) 2017-02-16
WO2010016527A1 (ja) 2010-02-11
CN102171570B (zh) 2014-10-15
CN102171570A (zh) 2011-08-31
PT2325648E (pt) 2014-06-24
RU2014111182A (ru) 2015-09-27
AU2009278387A1 (en) 2010-02-11
US20110136121A1 (en) 2011-06-09
HUE027332T2 (en) 2016-09-28
DK2325648T3 (da) 2014-07-28
KR20110052665A (ko) 2011-05-18
AU2009278387B2 (en) 2015-07-09
MX2011001445A (es) 2011-04-05
MX337991B (es) 2016-03-30
PL2325648T3 (pl) 2014-09-30
EP2325648A4 (en) 2011-09-28
RU2671497C2 (ru) 2018-11-01
DK2733492T3 (en) 2016-04-25
AU2015238877A1 (en) 2015-10-29
EP2325648B1 (en) 2014-04-23
JP2014134550A (ja) 2014-07-24
EP2325648A1 (en) 2011-05-25
BRPI0911925B1 (pt) 2024-01-30
BRPI0911925B8 (pt) 2024-02-06
KR101606779B1 (ko) 2016-03-28
CA2732980C (en) 2017-08-15
BRPI0911925A2 (pt) 2016-09-20
EP2733492B1 (en) 2016-02-24
RU2011108258A (ru) 2012-09-10
ES2471379T3 (es) 2014-06-26
ES2570731T3 (es) 2016-05-20
CA2732980A1 (en) 2010-02-11
JP5825386B2 (ja) 2015-12-02
JP5644110B2 (ja) 2014-12-24
RU2519089C2 (ru) 2014-06-10
US11137401B2 (en) 2021-10-05
EP2733492A1 (en) 2014-05-21
JPWO2010016527A1 (ja) 2012-01-26

Similar Documents

Publication Publication Date Title
PL2733492T3 (pl) Sposób wykrywania nowotworów
EP2585833A4 (en) Methods for detecting cancer
NO20085322L (no) Fremgangsmate for raskere ansiktsdeteksjon
BRPI0919116A2 (pt) método
BR112012004707A2 (pt) método
BR112012000624A2 (pt) método
FI20090389A0 (fi) Menetelmä
BRPI1013317A2 (pt) método de cimentação
PT3301446T (pt) Perfilagem molecular de tumores
BRPI0919705A2 (pt) método de comtrole geoquímico de fluidos de fraturamento
EP2437790A4 (en) conjugation
DK3106873T3 (da) Fremgangsmåde til detektering af cancer
EP2438197A4 (en) METHOD OF CANCER DETECTION
DK2313489T3 (da) Fremstillingsmetode
BRPI1012526A2 (pt) método
BRPI0813681A2 (pt) Detecção de coproantígeno de nematelminto
EP2294227A4 (en) CONCENTRATION TEST
EP2456440A4 (en) Quinolinone PDE2 INHIBITORS
EP2265950A4 (en) PROOF OF BIOMARKERS AND BIOMARKER COMPLEXES
BRPI1010705A2 (pt) método
DK2452189T3 (da) Fremgangsmåde til identifikation af forbindelser til behandling af cancer
EP2376923A4 (en) METHOD FOR DETECTING SEPSIS
BRPI0911625A2 (pt) Métodos
EP2402744A4 (en) AUFKOHLUNGSERKENNUNGSVERFAHREN
BRPI1012532A2 (pt) método